ESH MM 2018 | Daratumumab in myeloma update: expanding indications
Daratumumab has been a success in the treatment of multiple myeloma (MM), both as a monotherapy and in combination regimens. However, its success doesn’t end there; new indications and combinations are being explored for the antibody in MM, as well as a subcutaneous formulation to greatly improve treatment time and convenience. Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses these at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
Get great new content delivered to your inboxSign up